TearSolutions' lead product, called Lacripep, delivers what no other approved or pipeline drug has been able to: rapid healing of the ocular surface and relief of dry eye symptoms with a best-in-class safety and comfort profile. This was all proven in their first-in-human clinical trial which has led to formal written FDA alignment on our clinical and regulatory path to an unrestricted general Dry Eye indication (which is the same path a dry eye drug called Xiidra took, which sold to Novartis for $5.3B).
The company is raising capital to get Lacripep back into the clinic for the first of two Phase III trials.
Project Cure CEO Douglas Jackson, PhD shares the mission of Project Cure in a wide ranging discussion that illustrates the incredible supply chain expertise...
Maraia Tanner is the CEO of Star Harbor based in Lone Tree, Colorado. She shares insights into the mission of the organization and how...
Doug Freedberg, MD is a board-certified orthopedic surgeon (with sports medicine subspecialty certification) specializing in knee and shoulder arthroscopy, ACL reconstruction, sports medicine, golf...
